Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Humanigen
January 13, 2016
JP Morgan – Sector searches for ways to turn pricing debate
January 04, 2016
Pharma regulatory and development news over Christmas
November 19, 2015
Shkreli seeks new stream with KaloBios
July 17, 2015
Upcoming events: Pivotal data for Astra’s Mek and KaloBios looks for glimmer of light
April 10, 2015
Good times roll in Q1 as mid and small cap winners outnumber losers
December 24, 2014
Cyclacel and Neovacs enter the graveyard shift
October 06, 2014
Acquisitions help define performance of mid and small cap stocks
July 29, 2014
KaloBios's stumbles provide a lesson to enthusiastic IPO investors
April 08, 2014
Winners outweigh losers as small caps enjoy Q1's bull market
January 30, 2014
KaloBios takes its medicine and cuts losses in asthma
January 06, 2014
Fast times in biotech push IPO count to new highs
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 17, 2019
Vantage 2020 Preview
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Editor's Picks
January 28, 2020
The cost to Astrazeneca of building Brilinta
January 27, 2020
Rare diseases top another strong year for novel drug approvals
January 07, 2020
Surprise! There’s a tumour in which Keytruda doesn’t work
January 16, 2020
A quiet six months for device approvals
January 22, 2020
Sanofi's geriatric pipeline fails to freshen up
